News | 19 December 2025
Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The expansion includes a larger technical and service team and increased local procurement
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The new facility is expected to generate 500-600 new jobs in the region
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The company shall process the change of name application with BSE Ltd. in due course
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
India plays a critical role in Bristol Myers Squibb’s global strategy
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
This launch is part of the company's strategy to expand its nutraceutical portfolio
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Subscribe To Our Newsletter & Stay Updated
